---

2016

ルーム内検索
全46件   1  2  3 次の20件>>
ID
トピック名
閲覧/投稿
最新投稿
作成
328 【臨床研究】Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. 224 / 0
2016-10-17
KMF CRC
327 【基礎研究】Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. 163 / 0
2016-10-17
KMF CRC
326 【基礎研究】Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. 176 / 0
2016-10-17
KMF CRC
325 【基礎研究】DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. 157 / 0
2016-10-17
KMF CRC
324 【臨床研究】Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. 159 / 0
2016-10-17
KMF CRC
323 【レビュー】The immunotherapy era of myeloma: monoclonal antibodies, vaccines and adoptive T cell therapies. 158 / 0
2016-10-17
KMF CRC
322 【臨床研究】A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. 153 / 0
2016-10-17
KMF CRC
321 【基礎研究】Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. 186 / 0
2016-10-17
KMF CRC
320 【基礎研究】CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. 161 / 0
2016-10-17
KMF CRC
319 【臨床研究】Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. 221 / 0
2016-10-17
KMF CRC
318 【基礎研究】Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anti-cancer agent. 133 / 0
2016-10-17
KMF CRC
317 【基礎研究】Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstrテカm macroglobulinemia. 161 / 0
2016-10-17
KMF CRC
316 【臨床研究】Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. 171 / 0
2016-10-14
KMF CRC
315 【臨床研究】Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. 151 / 0
2016-10-14
KMF CRC
314 【臨床研究】Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. 161 / 0
2016-10-14
KMF CRC
313 【基礎研究】Hierarchy for targeting pro-survival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. 140 / 0
2016-10-14
KMF CRC
312 【基礎研究】Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. 154 / 0
2016-10-14
KMF CRC
311 【レビュー】A new era of immune therapy in multiple myeloma. 169 / 0
2016-10-14
KMF CRC
310 【基礎研究】A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. 136 / 0
2016-10-14
KMF CRC
309 【臨床研究】Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. 171 / 0
2016-10-14
KMF CRC
全46件   1  2  3 次の20件>>